Results 131 to 140 of about 2,408 (165)
Some of the next articles are maybe not open access.
Cytoreductive nephrectomy: past, present and future
Expert Review of Anticancer Therapy, 2014Cytoreductive nephrectomy (CN) is an integral part of the treatment of patients with metastatic renal cell carcinoma. Improved survival has been shown with CN and IFN-α. The introduction of targeted therapy for metastatic renal cell carcinoma has raised important questions regarding the role of CN.
Galazi, Myria +4 more
openaire +3 more sources
Cytoreductive laparoscopic radical nephrectomy
Urologic Oncology: Seminars and Original Investigations, 2001Abstract Laparoscopic radical nephrectomy is becoming increasingly utilized for localized renal tumors. We have applied this procedure to patients with metastatic disease for cytoreduction prior to systemic immunotherapy. Advantages of the laparoscopic approach include decreased parenteral narcotic requirement and decreased time to initiate systemic ...
Stephen E Pautler +2 more
openaire +1 more source
The role and timing of cytoreductive nephrectomy in the immunotherapy era
European Urology Focus, 2020The role and timing of cytoreductive nephrectomy in the immunotherapy era require further investigation. Extrapolation of data from the cytokine era that demonstrated an overall survival benefit of cytoreductive nephrectomy suggest that similar results might emerge from future trials using immunotherapy agents.
Emily C L, Wong, Anil, Kapoor
openaire +2 more sources
Cytoreductive nephrectomy: questions remain after CARMENA
Nature Reviews Urology, 2018Cytoreductive nephrectomy, a standard approach for de novo metastatic renal cell carcinoma in the era of cytokine therapy, has been upheld during the age of targeted therapy on the basis of retrospective data. Now, the first level I prospective data from the CARMENA and SURTIME trials challenge this standard.
Sumeet, Bhanvadia, Sumanta K, Pal
openaire +2 more sources
Cytoreductive nephrectomy in metastatic renal cell carcinoma
Expert Review of Anticancer Therapy, 2006Metastatic renal cell carcinoma is associated with a poor prognosis and a median survival time of only 6-12 months. However, the emergence of immunotherapies has rekindled interest in cytoreductive nephrectomy as a therapeutic option. Phase III randomized trials have demonstrated that cytoreductive nephrectomy significantly improves overall survival in
Kelly A, Healy +2 more
openaire +2 more sources
Cytoreductive nephrectomy in metastatic renal cancer
Current Urology Reports, 2003Recent randomized prospective trials have suggested that cytoreductive nephrectomy confers a survival advantage in patients with metastatic renal cancer who receive immunotherapy with interferon-alfa-2b. It appears that the patients most benefiting from this approach are those with good performance status, lung-only metastases, and adequate cardiac and
openaire +2 more sources
Cytoreductive nephrectomy in metastatic renal cell carcinoma
Current Opinion in Urology, 2008Cytoreductive nephrectomy has an established role in management of metastatic renal cell carcinoma when performed in properly selected patients prior to administration of systemic cytokine therapy. Within the past several years, novel molecular targeted agents have not only revolutionized management of metastatic renal cell carcinoma but also created ...
Vitaly, Margulis +2 more
openaire +2 more sources
Is cytoreductive nephrectomy relevant in the immunotherapy era?
Current Opinion in Urology, 2019The recent approval of immune checkpoint inhibitors (ICI) revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). However, the role of cytoreductive nephrectomy is not well defined in this setting. Here, we review the contemporary role and timing of cytoreductive nephrectomy for advanced RCC in the era of immunotherapy ...
Nirmish, Singla +2 more
openaire +2 more sources
In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy
European Urology, 2013The risk of in-hospital mortality after cytoreductive nephrectomy (CNT) is non-negligible and may vary widely according to various patient and hospital characteristics and clinical contexts.To better elucidate the mechanisms underlying variability in operative mortality after CNT.Using the US-based Nationwide Inpatient Sample registry, a weighted ...
Trinh QD +9 more
openaire +2 more sources
Perioperative outcomes of cytoreductive nephrectomy in the
Objectives To define the perioperative morbidity and 30‐day mortality of cytoreductive nephrectomy ( CN ) using the B ritish Association of Urological Surgeons ( BAUS
Benjamin L. Jackson +2 more
openaire +2 more sources